<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001688327</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>4</amendmentNo>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <dateOfEvent>02/06/2026</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001819133</issuerCIK>
        <issuerCUSIP>87583X109</issuerCUSIP>
        <issuerName>Tango Therapeutics, Inc.</issuerName>
        <address>
          <street1 xmlns="http://www.sec.gov/edgar/common">201 Brookline Avenue</street1>
          <street2 xmlns="http://www.sec.gov/edgar/common">Suite 1401</street2>
          <city xmlns="http://www.sec.gov/edgar/common">Boston</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">02215</zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Third Rock Ventures, LLC</personName>
          <personPhoneNum>617-585-2000</personPhoneNum>
          <personAddress>
            <street1 xmlns="http://www.sec.gov/edgar/common">201 Brookline Avenue</street1>
            <street2 xmlns="http://www.sec.gov/edgar/common">Suite 1401</street2>
            <city xmlns="http://www.sec.gov/edgar/common">Boston</city>
            <stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
            <zipCode xmlns="http://www.sec.gov/edgar/common">02215</zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001688327</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Third Rock Ventures IV, L.P.</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>6374574</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>6374574</sharedDispositivePower>
        <aggregateAmountOwned>6374574</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.74</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>The percent of class was calculated based on 134,593,998 shares of common stock issued and outstanding as of October 28, 2025, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 4, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001688326</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Third Rock Ventures GP IV, L.P.</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>6374574</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>6374574</sharedDispositivePower>
        <aggregateAmountOwned>6374574</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.74</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>The percent of class was calculated based on 134,593,998 shares of common stock issued and outstanding as of October 28, 2025, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 4, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001688325</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>TRV GP IV, LLC</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>6374574</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>6374574</sharedDispositivePower>
        <aggregateAmountOwned>6374574</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.74</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>The percent of class was calculated based on 134,593,998 shares of common stock issued and outstanding as of October 28, 2025, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 4, 2025.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock</securityTitle>
        <issuerName>Tango Therapeutics, Inc.</issuerName>
        <issuerPrincipalAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">201 Brookline Avenue</street1>
          <street2 xmlns="http://www.sec.gov/edgar/common">Suite 1401</street2>
          <city xmlns="http://www.sec.gov/edgar/common">Boston</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">02215</zipCode>
        </issuerPrincipalAddress>
        <commentText>This Amendment No. 4 (this "Amendment") amends and supplements the Schedule 13D (as amended, the "Schedule 13D") filed by the Reporting Persons with respect to the shares of common stock, $0.001 par value per share ("Common Stock"), of Tango Therapeutics, Inc. (the "Company" or the "Issuer"). The transactions described in Item 5(c) resulted in a decrease of over one percent (1%) in the aggregate percentage ownership reported by the Reporting Persons in the Schedule 13D. Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Schedule 13D.</commentText>
      </item1>
      <item5>
        <percentageOfClassSecurities>As of February 6, 2026, TRV IV had shared voting and dispositive power with respect to 6,374,574 shares of the Issuer's Common Stock, constituting approximately 4.74% of the Issuer's outstanding Common Stock.

As of February 6, 2026, Third Rock Ventures GP IV, L.P. ("TRV GP IV"), as the general partner of TRV IV may be deemed to have shared voting and dispositive power with respect to all 6,374,574 shares of the Issuer's Common Stock owned by TRV IV, constituting approximately 4.74% of the Issuer's outstanding Common Stock.

As of February 6, 2026, TRV GP IV, LLC ("TRV GP IV LLC," and collectively with TRV IV and TRV GP IV, the "Reporting Persons"), as the general partner of TRV GP IV may be deemed to have shared voting and dispositive power with respect to all 6,374,574 shares of the Issuer's Common Stock owned by TRV IV, constituting approximately 4.74% of the Issuer's outstanding Common Stock.

The percent of class was calculated based on 134,593,998 shares of common stock issued and outstanding as of October 28, 2025, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on Novemebr 4, 2025.

Except as set forth in the table below, no transactions in the Common Stock were effected by the Reporting Persons during the 60-day period ended February 6, 2026.

                  Date              Amount of Securities    Price per Share             Where and How Effected
TRV IV   1/21/2026                350,000                          $12.52*                  Disposed in the Open Market
TRV IV   1/22/2026                253,383                          $12.56*                  Disposed in the Open Market
TRV IV    2/3/2026                 500,000                          $12.59*                  Disposed in the Open Market
TRV IV    2/6/2026                 396,617                          $12.57*                  Disposed in the Open Market
* The price reported is a weighted average price. These shares were sold in multiple transactions.</percentageOfClassSecurities>
        <numberOfShares>Regarding the number of shares as to which such person has:

(i) sole power to vote or to direct the vote: See line 7 of cover sheets

(ii) shared power to vote or to direct the vote: See line 8 of cover sheets

(iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets.

(iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets </numberOfShares>
        <transactionDesc>Except as set forth in the table below, no transactions in the Common Stock were effected by the Reporting Persons during the 60-day period ended February 6, 2026.</transactionDesc>
        <date5PercentOwnership>2/6/2026</date5PercentOwnership>
      </item5>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Third Rock Ventures IV, L.P.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Kevin Gillis</signature>
          <title>Kevin Gillis, COO of TRV GP IV, LLC, the general partner of Third Rock Ventures GP IV, L.P., the general partner of Third Rock Ventures IV, L.P.</title>
          <date>02/10/2026</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Third Rock Ventures GP IV, L.P.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Kevin Gillis</signature>
          <title>Kevin Gillis, COO of TRV GP IV, LLC, the general partner of Third Rock Ventures GP IV, L.P.</title>
          <date>02/10/2026</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>TRV GP IV, LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Kevin Gillis</signature>
          <title>Kevin Gillis,  COO</title>
          <date>02/10/2026</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
